Biotech Values

[scott2987]

Momenta Pharma (MNTA): Upgraded to Overweight from Underweight at Morgan Stanley
More News related to MNTA
Momenta Pharma (MNTA): Upgraded to Overweight from Underweight at Morgan Stanley
Morgan Stanley Upgrades Momenta Pharma (MNTA) to Overweight
Momenta Pharmaceuticals to Present At 2008 Morgan Stanley Global Healthcare Unplugged Conference
Momenta Pharmaceuticals Announces Presentation of M118 Phase 1 Results At the American Society for Clinical Pharmacology and Therapeutics Annual Meeting
Momenta Pharmaceuticals to Present At Cowen and Company 28th Annual Health Care Conference
More News related to MNTA
More News related to Upgrades
Momenta Pharma (MNTA): Upgraded to Overweight from Underweight at Morgan Stanley
Credit Suisse upgrades US Airways (LCC) to Outperform
Citi Upgrades Masimo (MASI) to Buy
J.P. Morgan Upgrades Big Lots (BIG) to Overweight
Bear Stearns Upgrades Credit Suisse (CS) to Peer Perform
More News related to Upgrades
April 28, 2008 9:00 AM EDT


From Notable Calls

Morgan Stanley is upgrading Momenta Pharma (NASDAQ: MNTA) to Overweight-V and increasing their target to $22. Firm believes the stars could be finally aligning for the FDA approval of MNTA/NVS’s M-Enox in 2008-09 as the only genericversion of SNY’s Lovenox (blood thinner), potentially leading to: 1) 40-50% share of the $1.5+ billion U.S. Lovenox market, 2) peak potential earnings of $3/sh and 3) a share price of $40+. The downside risk of a long delay or non-approval is that the stock returns to $6.

Why are they upgrading now? Firm believes that the heparin (a complex sugar) contamination crisis may have given MNTA the unique opportunity to prove to the FDA its proprietary technology for characterizing complex sugars. Last week’s Nature publication shows that MNTA worked with the FDA to identify the heparin contaminant. They view this work as a game changer, underestimated by the Street. In our opinion, the FDA is now more likely to view MNTA’s technology as sufficient to show that M-Enox is the same as Lovenox (also a complex sugar) — a key regulatory hurdle and one they feel competitors Teva and Amphastar cannot achieve.

Notablecalls: This is a game-changing upgrade for this stock. Morgan Stanley has been neg on MNTA for quiet some time (UW rating) and now they are saying the stock could do $35+ under bullish scenario.

I expect to see a 10%-15% upside move in MNTA today.



For more calls go to http://notablecalls.blogspot.com/





Related Categories
Contributors
Upgrades


Stocks Mentioned
MNTA 14.32
+1.07 +8.08%
Volume: 0
Track MNTA


Related Entities
Morgan Stanley


Add Your Comment
Name
Subject
Body
Verification can't see the text?
click here to refresh the image.
what's this?




Sign up for StreetInsider Free!
Recieve full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!